Chimerix To Present At Therapeutic Area Partnerships Meeting

RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that President and Chief Executive Officer Kenneth I. Moch will present at the 2012 Therapeutic Area Partnerships meeting in Boston, MA.  His presentation will include an update on the company's clinical pipeline, including its lead development compound, CMX001, which was named by conference organizers a "Top 10 Project to Watch in Infectious Diseases." 

Mr. Moch will be presenting on Thursday, November 29 at 3:50 p.m. EST at the Westin Copley Place during the Infectious Diseases Projects to Watch session.  Therapeutic Area Partnerships is regarded as one of the industry's premier biopharmaceutical partnering event.  More information can be found on the meeting's web site:  www.tapartnerships.com.  

About Chimerix
Chimerix is developing novel oral antiviral therapeutics with the potential to improve outcomes for patients in multiple therapeutic areas, including transplant, oncology, acute care and global health. The Company's proprietary lipid technology has given rise to two clinical-stage lipid acyclic nucleoside phosphonates that have demonstrated the potential for enhanced activity and safety compared with currently approved drugs.

Chimerix's lead clinical-stage drug candidate, CMX001, is a novel, broad-spectrum, oral antiviral that inhibits double-stranded DNA (dsDNA) viruses, including cytomegalovirus (CMV), adenovirus (AdV), BK virus and herpes simplex virus. CMX001 has completed Phase 2 clinical development for the prophylaxis of CMV in hematopoietic stem cell transplant (HSCT) recipients and is in Phase 2 development for the preemption and treatment of AdV infection. To date, more than 800 patients have been dosed with CMX001 in controlled clinical trials and open-label treatment protocols. Chimerix has completed an End of Phase 2 meeting with the U.S. Food and Drug Administration and is preparing to initiate Phase 3 clinical development of CMX001 for the prophylaxis of CMV in HSCT recipients in 2013.

In addition to its commercial use, CMX001 is being developed under a contract from the Biomedical Advanced Research and Development Authority (BARDA) as a medical countermeasure to protect against a bioterror threat in the event of a smallpox release.

In July 2012, Chimerix granted an exclusive worldwide license to Merck for the development and commercialization of its second clinical-stage drug candidate, CMX157, for the treatment of HIV infection, further validating the Company's propriety lipid technology.

For more information, please visit www.chimerix.com.

SOURCE Chimerix, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED